Tumor Ablation Market - Size, Share, Industry Trends, and Forecasts (2024 - 2031)

By Type:

Based on type, the market is categorized into radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, percutaneous ethanol ablation (PEI), and others.

Trends in the Type:

• Real-time imaging techniques like ultrasound, CT, and MRI allow for precise targeting of tumors, minimizing damage to surrounding healthy tissue.
• Emerging technologies such as microwave ablation, laser ablation, and high-intensity focused ultrasound (HIFU) are offering more precise and effective treatments.

The radiofrequency ablation (RFA) segment accounted for the largest tumor ablation market share in 2023.

• Radiofrequency ablation (RFA) is a minimally invasive procedure used to treat tumors in various organs, including the liver, kidney, lung, and bone among others.
• During RFA, a thin probe is inserted into the tumor, and high-frequency electrical currents are delivered through the probe to heat and destroy the tumor cells. This heat generation causes cell death and coagulation of tissue proteins, effectively eliminating the tumor.
• RFA offers several advantages over traditional surgery, such as shorter hospital stays, less pain, and a quick recovery time.
• It is particularly useful for patients who are not suitable for surgery or radiation therapy due to their overall health or the location and size of the tumor.
• Manufacturers are introducing novel RFA solutions, for destroying tumors.
• For instance, in April 2023, Compal Electronics introduced the AblatePal. This innovative system utilizes radiofrequency ablation (RFA) technology to effectively destroy tumor cells. The AblatePal system is designed to offer precise and efficient tumor ablation, providing a less invasive alternative to traditional surgical procedures.
• Thus, as per the analysis, the use of RFA for ablation of cancer treatment is driving the tumor ablation market trends.

The cryoablation segment is expected to grow at the fastest CAGR over the forecast period.

• Cryoablation is a minimally invasive procedure that uses extreme cold to freeze and destroy abnormal cells or diseased tissue, including cancerous tumors.
• During the procedure, a thin, needle-like probe, called a cryoprobe, is inserted into the tumor.
• A freezing agent, such as liquid nitrogen or argon gas, is then delivered through the probe, causing the tissue to freeze and form ice crystals. This freezing process damages the cells, leading to their death.
• The freezing and thawing cycles are repeated several times to ensure the breakdown of the tumor.
• Cryoablation is often used to treat tumors in the liver, kidney, lung, bone, and prostate.
• Thus, as per the analysis, the use of cryoablation is driving the development of the segment in the coming years.

By Application:

Based on applications, the market is categorized into liver cancer, lung cancer, kidney cancer, bone cancer, and others

The liver cancer segment accounted for the largest tumor ablation market share in 2023.

• Tumor ablation is a minimally invasive procedure used to treat liver cancer. It involves destroying cancerous cells using various techniques, including radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation among others.
• In RFA, high-frequency electrical currents are delivered through a probe inserted into the tumor, generating heat that destroys the cancer cells present in the liver.
• MWA uses microwave energy to heat and destroy tumor tissue in the liver.
• Cryoablation involves freezing the liver tumor cells with extreme cold, causing them to die.
• These techniques offer several advantages over traditional surgery, including smaller incisions, shorter recovery time, and less pain. Tumor ablation is particularly beneficial for patients who are not suitable for surgery or radiation therapy due to their overall health or the location and size of the liver tumor.
• Various manufacturers are introducing novel solutions for liver tumors.
• For instance, Johnson & Johnson provides the NEUWAVE™ Microwave System which is intended for percutaneous, open, and laparoscopic ablation of soft tissue, specifically for the partial or complete ablation of non-resectable liver tumors.
• Thus, based on the analysis, the rising trends for the use of ablation solutions for liver cancer are influencing the tumor ablation market expansion.

The breast cancer segment is expected to grow at the fastest CAGR over the forecast period.

• Breast cancer is a disease that occurs when cells in the breast grow uncontrollably, forming a tumor. It is one of the most common types of cancer affecting women worldwide.
• While traditional surgical options like lumpectomy and mastectomy remain the primary treatments, ablation therapies like radiofrequency ablation (RFA) and cryoablation are being explored for specific cases.
• RFA and cryoablation involve using heat or extreme cold to destroy tumor cells.These minimally invasive techniques are considered for small, early-stage breast tumors in select patients.
• Overall, as research continues to evolve, further advancements in ablation technologies are being introduced, expanding their role in breast cancer treatment, thus driving the tumor ablation market trends.

By End User:

Based on end users, the market is categorized into hospitals and clinics, cancer care centers, and ambulatory surgical centers.

Trends in the End User:

• There is a growing trend for minimally invasive procedures in places equipped with advanced solutions.
• The growing trends for same-day procedures are influencing the segment

The hospitals and clinics segment accounted for the largest market share of 54.77% in the year 2023.

• Hospitals and clinics serve a crucial role as primary centers for the comprehensive treatment of cancer, offering a sophisticated ecosystem of medical expertise and advanced technologies.
• Modern hospital-based management monitors for early signs of this condition. They play a major and crucial role in helping patients by providing convenient, affordable, and easy access to the treatment of cancer.
• The inpatient treatment approach in hospitals has evolved to encompass a multidisciplinary approach making availability of cancer specialists in a single place. Moreover, hospitals increasingly invest in facilities equipped with specialized equipment and offer advanced solutions.
• For instance, in 2022, American Hospital, Dubai made a significant stride in minimally invasive cancer treatment by performing the first cryoablation procedure for kidney cancer in the Middle East and North Africa (MENA) region. This innovative technique offers a less invasive alternative to traditional surgical methods, providing patients with a quick recovery time and reduced risk of complications.
• Thus, as per the analysis, owing to the aforementioned factors, hospitals serve a pivotal role in the treatment, providing comprehensive care in the

The ambulatory surgical center segment is expected to grow at the fastest CAGR over the forecast period.

• Ambulatory surgery centers, or ASCs, are modern healthcare facilities focused on providing same-day care and ablation procedures. These settings offer a convenient and cost-effective alternative to traditional hospitals for a variety of cancer procedures.
• ASCs are designed to handle procedures that do not require overnight hospitalization, allowing patients to go home on the same day. Ambulatory surgical centers are increasingly playing a role in managing patients.
• ASCs are equipped with novel technology and experienced medical professionals to ensure the safety and efficacy of ablation procedures.
• These minimally invasive procedures, such as radiofrequency ablation (RFA) and cryoablation, target and destroy tumor cells using heat or cold, respectively. The advantages of performing tumor ablation in ASCs include shorter recovery times, reduced hospital stays, and lower costs compared to traditional hospital settings.
• Overall, as per the tumor ablation market analysis, as technology advances and patient preferences evolve, ASCs are becoming a preferred venue for delivering high-quality, minimally invasive cancer care.